Neuroprotective Potentials of Panax Ginseng Against Alzheimer’s Disease: A Review of Preclinical and Clinical Evidences

Li, Jing; Huang, Qingxia; Chen, Jinjin; Qi, Hongyu; Liu, Jiaqi; Chen, Zhaoqiang; Zhao, Daqing; Wang, Zeyu; Li, Xiangyan

doi:10.3389/fphar.2021.688490

Cited by 29 publications

(31 citation statements)

References 95 publications

(105 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the case of oncology, this is likely caused by generally poor prognosis of patients with different kinds of cancer who have run out of approved treatments [ 22 ]. The high number of expanded access studies in neurology may be associated with the fact that some relatively frequent chronic neurological diseases (eg, Alzheimer’s disease) do not have effective treatments [ 23 ]. The high demand for unapproved treatments in infectious diseases can be a result of the development of resistance to approved drugs [ 24 , 25 ].…”

Section: Discussionmentioning

confidence: 99%

ClinicalTrials.gov as a Source of Information About Expanded Access Programs: Cohort Study

Borysowski

Górski

2021

J Med Internet Res

View full text Add to dashboard Cite

Background ClinicalTrials.gov (CT.gov) is the most comprehensive internet-based register of different types of clinical studies. Expanded access is the use of unapproved drugs, biologics, or medical devices outside of clinical trials. One of the key problems in expanded access is the availability to both health care providers and patients of information about unapproved treatments. Objective We aimed to evaluate CT.gov as a potential source of information about expanded access programs. Methods We assessed the completeness of information in the records of 228 expanded access programs registered with CT.gov from February 2017 through May 2020. Moreover, we examined what percentage of published expanded access studies has been registered with CT.gov. Logistic regression (univariate and multivariate) and mediation analyses were used to identify the predictors of the absence of some information and a study’s nonregistration. Results We found that some important data were missing from the records of many programs. Information that was missing most often included a detailed study description, facility information, central contact person, and eligibility criteria (55.3%, 54.0%, 41.7%, and 17.5% of the programs, respectively). Multivariate analysis showed that information about central contact person was more likely to be missing from records of studies registered in 2017 (adjusted OR 21.93; 95% CI 4.42-172.29; P<.001). This finding was confirmed by mediation analysis (P=.02). Furthermore, 14% of the programs were registered retrospectively. We also showed that only 33 of 77 (42.9%) expanded access studies performed in the United States and published from 2014 through 2019 were registered with CT.gov. However, multivariate logistic regression analysis showed no significant association between any of the variables related to the studies and the odds of study nonregistration (P>.01). Conclusions Currently, CT.gov is a quite fragmentary source of data on expanded access programs. This problem is important because CT.gov is the only publicly available primary source of information about specific programs. We suggest the actions that should be taken by different stakeholders to fully exploit this register as a source of information about expanded access.

show abstract

Section: Discussionmentioning

confidence: 99%

ClinicalTrials.gov as a Source of Information About Expanded Access Programs: Cohort Study

Borysowski

Górski

2021

J Med Internet Res

View full text Add to dashboard Cite

show abstract

“…In conclusion, Panax ginseng , a well-known medicinal plant that contains ginsenosides, gintonin, and other components, has neuroprotective effects in neuronal cells and animal models by stimulation of BDNF expression in AD. The findings from clinical trials further indicate that Panax ginseng or its formula treatment is safe and has a positive effect on cognition in patients with AD [ 81 – 83 ]. Therefore, it is of great value to carry out clinical trial research to further evaluate the therapeutic effects of ginseng, formulas, and combinations with other TCM and drugs, in patients with different stages of AD, and further explore the underlying molecular mechanisms of neuroprotection [ 84 ].…”

Section: Neuroprotection Towards Programmed Cell Death Induced By a ...mentioning

confidence: 99%

Current Progress on Neuroprotection Induced by Artemisia, Ginseng, Astragalus, and Ginkgo Traditional Chinese Medicines for the Therapy of Alzheimer’s Disease

Qin

Rubin

Silva

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Aging is associated with the occurrence of diverse degenerative changes in various tissues and organs and with an increased incidence of neurological disorders, especially neurodegenerative diseases such as Alzheimer’s disease (AD). In recent years, the search for effective components derived from medicinal plants in delaying aging and preventing and treating neurodegenerative diseases has been increasing and the number of related publications shows a rising trend. Here, we present a concise, updated review on the preclinical and clinical research progress in the assessment of the therapeutic potential of different traditional Chinese medicines and derived active ingredients and their effect on the signaling pathways involved in AD neuroprotection. Recognized by their multitargeting ability, these natural compounds hold great potential in developing novel drugs for AD.

show abstract

“…Although CK is regarded as safe and well-tolerated, findings from clinical trials are marginal and based on CK-rich fermented red ginseng. Delivery of CK through nanocarriers was reported to override its limitations of efflux, poor water solubility, and membrane permeability, which impeded the research progress into clinical trials [60,61].…”

Section: Nano-phytopharmaceuticals In Neurological (Cns) Disordersmentioning

confidence: 99%

Precision and Advanced Nano-Phytopharmaceuticals for Therapeutic Applications

et al. 2022

View full text Add to dashboard Cite

Phytopharmaceuticals have been widely used globally since ancient times and acknowledged by healthcare professionals and patients for their superior therapeutic value and fewer side-effects compared to modern medicines. However, phytopharmaceuticals need a scientific and methodical approach to deliver their components and thereby improve patient compliance and treatment adherence. Dose reduction, improved bioavailability, receptor selective binding, and targeted delivery of phytopharmaceuticals can be likely achieved by molding them into specific nano-formulations. In recent decades, nanotechnology-based phytopharmaceuticals have emerged as potential therapeutic candidates for the treatment of various communicable and non-communicable diseases. Nanotechnology combined with phytopharmaceuticals broadens the therapeutic perspective and overcomes problems associated with plant medicine. The current review highlights the therapeutic application of various nano-phytopharmaceuticals in neurological, cardiovascular, pulmonary, and gastro-intestinal disorders. We conclude that nano-phytopharmaceuticals emerge as promising therapeutics for many pathological conditions with good compliance and higher acceptance.

show abstract

Neuroprotective Potentials of Panax Ginseng Against Alzheimer’s Disease: A Review of Preclinical and Clinical Evidences

Cited by 29 publications

References 95 publications

ClinicalTrials.gov as a Source of Information About Expanded Access Programs: Cohort Study

ClinicalTrials.gov as a Source of Information About Expanded Access Programs: Cohort Study

Current Progress on Neuroprotection Induced by Artemisia, Ginseng, Astragalus, and Ginkgo Traditional Chinese Medicines for the Therapy of Alzheimer’s Disease

Precision and Advanced Nano-Phytopharmaceuticals for Therapeutic Applications

Contact Info

Product

Resources

About